Cambridge cancer drug startup Nuvalent raises $135 million
The new funding comes just four months after it was launched with $50 million.
By Jonathan Saltzman Globe Staff,Updated May 11, 2021, 6:00 a.m.
Email to a Friend
James Porter is CEO of Cambridge biotech Nuvalent.Nuvalent
Nuvalent, a Cambridge biotech working on precision cancer drugs, has raised another $135 million in venture capital just four months after the firm was launched with $50 million in financing.
The startup is developing lung cancer drugs that rely on enzyme blockers known as kinase inhibitors to help keep cancer cells from growing. Nuvalent hopes to use cash from the second round of financing to advance two potential drugs into clinical trials.